NEW YORK (RLPC) - Valeant Pharmaceuticals International () is offering to pay lenders a higher interest rate in order to obtain an amendment to its debt agreement that would loosen one of its covenants, according to sources.
The company previously obtained an amendment earlier this year to help stave off default, allowing it additional time to file its financial statements with securities regulators. Joe Papa, Valeant's chief executive officer, said on a conference call Tuesday that the company would seek to...
More